Drugs /
lam-003
Back to Drugs List
Overview
NCI Definition [1]:
An orally bioavailable immunomodulating agent with potential antineoplastic activity.
Clinical Trials
Lam-003 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lam-003, 1 is phase 1 (1 open).
Acute myeloid leukemia is the most common disease being investigated in lam-003 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
